NCT05275673View on ClinicalTrials.gov

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

January 24, 2023

Study Completion Date

January 24, 2023

Conditions
Non-Small Cell Lung CancerSquamous Non-small-cell Lung CancerSquamous Non-Small Cell Neoplasm of LungNFE2L2 Gene Mutation
Interventions
DRUG

sapanisertib

capsules for oral administration

Trial Locations (14)

10065

Memorial Sloan Kettering Cancer Center - Thoracic, New York

15232

UPMC Cancer Pavilion, Pittsburgh

22031

Virginia Cancer Specialist, PC, Fairfax

32308

Florida Cancer Specialists, Tallahassee

33901

Florida Cancer Specialists, Fort Myers

34474

Ocala Oncology Center, Ocala

37203

Tennessee Oncology, Nashville

40202

Norton Cancer Institute, Downtown, Louisville

43219

Zangmeister Cancer Center, Columbus

48201

Karmanos Cancer Institute, Detroit

63110

Washington University - Patient Care Coordinator Center, St Louis

95403

Providence Medical Group Santa Rosa - Cancer Center, Santa Rosa

95817

UC Davis Comprehensive Cancer Center, Davis

97213

Providence Cancer Institute Franz Clinic, Portland

Sponsors

Lead Sponsor

Faeth Therapeutics
All Listed Sponsors
lead

Faeth Therapeutics

INDUSTRY

NCT05275673 - A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter